Coramaze Technologies Overview
Coramaze Technologies develops the Tripair, a simple, rapid, and effective percutaneous treatment for tricuspid valve disease. The treatment is intended to improve quality of life and reduce morbidity for heart failure patients suffering from tricuspid regurgitation. The Tripair implant is anchored a-traumatically in the right atrium, enabling full retrievability and intraprocedural efficacy evaluation while reducing regurgitation even in the most severe cases.
Cumulative Funding Raised Over Time ($)
$1.1MFeb 2014
$6.3MSep 2015
Latest News
growth-positive
Coramaze Technologies Raises EUR 4.5 Million for Mitramaze Valve Repair System
Abiomed has received funding for a clinical trial of a novel transfemoral mitral valve repair system with atraumatic anchoring. The funding will support the development and testing of the new technology.
Investment
growth-positive
coramaze technologies GmbH receives € 1 million to develop an innovative medical device for the minimally invasive treatment of heart valve diseases
coramaze technologies GmbH, a German medical device company, has raised €1 million in seed funding to advance the development of its mitramaze® valve repair system for the treatment of mitral regurgitation. The funding round was led by High-Tech Gründerfonds and Seed Capital Dortmund. The companys technology offers a less traumatic and more efficient alternative to existing treatments, with the potential to become the standard treatment for inoperable patients. The mitramaze® valve repair system is currently in pre-clinical development and has shown promising results in reducing mitral regurgitation. The company plans to use the funding to further advance pre-clinical development and prepare for the subsequent clinical development phase.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6.26M |
| Last funding | $5.15M |
| Stage | A |
| Rounds | 2 |
| Investors | 4 |
Team Members
0
Employees: 11-50
Web & Social Links
| Website | tripairtechnology.com |
Locations
Totseret ha-Arets St 3, Petah Tikva, Israel
Photos & Videos
2 item(s)
Coramaze Technologies Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesImplantsTags (9)
heart-failurevascularcardiologycathetersminimally-invasiveheart-diseasesmedical-technologiescardiovascularmedical-devicesGeographic Markets
East AsiaEuropeOceaniaNorth AmericaCoramaze Technologies Financials
$6.26M
Total funding
Undisclosed
Capital raised
$5.15M
Last funding
A
Funding stage
2
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$1.1MFeb 2014
$6.3MSep 2015
Private Equity Funding
A Round
Sep 2015
$5.15M
Elron Ventures (Lead)
,
High Tech Grnderfonds, Seed Capital Dortmund
Seed
Feb 2014
$1.11M
Seed Capital Dortmund (Lead)
,
High Tech Grnderfonds, German Federal Ministry of Economics and Technology
Coramaze Technologies Lifecycle
Cumulative Funding Raised Over Time
$1.1MFeb 2014
$6.3MSep 2015
All Events
A Round
Sep 2015
$5.15M
Elron Ventures (Lead)
,
High Tech Grnderfonds, Seed Capital Dortmund
Seed
Feb 2014
$1.11M
Seed Capital Dortmund (Lead)
,
High Tech Grnderfonds, German Federal Ministry of Economics and Technology
Coramaze Technologies News
2 articles
growth-positive
Coramaze Technologies Raises EUR 4.5 Million for Mitramaze Valve Repair System
Abiomed has received funding for a clinical trial of a novel transfemoral mitral valve repair system with atraumatic anchoring. The funding will support the development and testing of the new technology.
Investment
growth-positive
coramaze technologies GmbH receives € 1 million to develop an innovative medical device for the minimally invasive treatment of heart valve diseases
coramaze technologies GmbH, a German medical device company, has raised €1 million in seed funding to advance the development of its mitramaze® valve repair system for the treatment of mitral regurgitation. The funding round was led by High-Tech Gründerfonds and Seed Capital Dortmund. The companys technology offers a less traumatic and more efficient alternative to existing treatments, with the potential to become the standard treatment for inoperable patients. The mitramaze® valve repair system is currently in pre-clinical development and has shown promising results in reducing mitral regurgitation. The company plans to use the funding to further advance pre-clinical development and prepare for the subsequent clinical development phase.
Investment
Coramaze Technologies Team
No team members listed.
Employee Info
| Employees (range) | 11-50 |
| Exact count | 21 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Coramaze Technologies Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | markets, external profiles |
| BI Verification | Yotam Maman |
| Registrar ID | 515736411 |
| Crunchbase | coramaze-technologies |
| Creator | Matan Eblagon |
| Creator email | matane@sncentral.org |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2022-11-17T00:00:00.000Z |
| Created | 2021-12-08T00:00:00.000Z |
| Claimed | Yes |